{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:48:51Z","timestamp":1786546131601,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurol.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:58:35Z","timestamp":1779911915000},"page":"615-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Six-month outcomes of subcutaneous foslevodopa\/foscarbidopa according to initiation setting in advanced Parkinson's disease: A retrospective cohort study"],"prefix":"10.1016","volume":"182","author":[{"given":"C.","family":"Desjardins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"de Saint Vaulry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Salardaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Brandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Baille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.05.001_bib0080","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.05.001_bib0085","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson's disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study","volume":"12","author":"Aldred","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurol.2026.05.001_bib0090","doi-asserted-by":"crossref","first-page":"100239","DOI":"10.1016\/j.prdoa.2024.100239","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: considerations for initiation and maintenance","volume":"10","author":"Fung","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2026.05.001_bib0095","first-page":"1","article-title":"Real-world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations","volume":"133","author":"Koeglsperger","year":"2025","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2026.05.001_bib0100","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","article-title":"Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty","volume":"130","author":"Auffret","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.neurol.2026.05.001_bib0105","doi-asserted-by":"crossref","first-page":"208","DOI":"10.14802\/jmd.23172","article-title":"Accessibility of device-aided therapies for persons with Parkinson's disease in Poland","volume":"17","author":"Smilowska","year":"2023","journal-title":"J Mov Disord"},{"key":"10.1016\/j.neurol.2026.05.001_bib0110","doi-asserted-by":"crossref","first-page":"e0316052","DOI":"10.1371\/journal.pone.0316052","article-title":"Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study. The DATs-PD GETM Spanish Registry Protocol Study","volume":"20","author":"Santos-Garc\u00eda","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2026.05.001_bib0115","doi-asserted-by":"crossref","first-page":"106065","DOI":"10.1016\/j.parkreldis.2024.106065","article-title":"\u201cAdvanced\u201d Parkinson's disease: a review","volume":"123","author":"Aslam","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2026.05.001_bib0120","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/brainsci14121244","article-title":"Use of the MNCD classification to monitor clinical stage and response to levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease","volume":"14","author":"Santos-Garc\u00eda","year":"2024","journal-title":"Brain Sci"},{"key":"10.1016\/j.neurol.2026.05.001_bib0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41531-025-01093-x","article-title":"Parkinson's disease quality of life at 12 months comparing invasive device-aided therapy with oral treatment","volume":"11","author":"Ramirez-Zamora","year":"2025","journal-title":"NPJ Parkinsons Dis"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neurol.2026.05.001_bib0130","doi-asserted-by":"crossref","first-page":"107889","DOI":"10.1016\/j.parkreldis.2025.107889","article-title":"No one size fits all approach with apomorphine initiation","volume":"139","author":"Kobylecki","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2026.05.001_bib0135","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/brainsci13050736","article-title":"Device-aided therapies in Parkinson's disease\u00a0\u2014\u00a0results from the German Care4PD study","volume":"13","author":"Fr\u00fcndt","year":"2023","journal-title":"Brain Sci"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.neurol.2026.05.001_bib0140","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1007\/s10072-008-1054-7","article-title":"Continuous dopaminergic stimulation achieved by duodenal levodopa infusion","volume":"29","author":"Odin","year":"2008","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2026.05.001_bib0145","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00702-023-02609-6","article-title":"Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study","volume":"130","author":"Zagnoli","year":"2023","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2026.05.001_bib0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.parkreldis.2020.07.005","article-title":"The association between pain and impulse control behaviours in Parkinson's disease","volume":"78","author":"Kobylecki","year":"2020","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872600531X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872600531X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:52:09Z","timestamp":1786542729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537872600531X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S003537872600531X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.001","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six-month outcomes of subcutaneous foslevodopa\/foscarbidopa according to initiation setting in advanced Parkinson's disease: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}